A Study of HRS-7535 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Diet and Exercise
NCT ID: NCT06672172
Last Updated: 2025-04-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
284 participants
INTERVENTIONAL
2024-09-25
2026-04-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin
NCT06589765
A 16 Week Study of HRS-7535 in Adults With Type 2 Diabetes Mellitus
NCT05759897
Efficacy and Safety of HRS-7535 Tablets in T2DM Subjects Poorly Controlled With Metformin and SGLT2i.
NCT06393348
the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise Alone
NCT06650007
Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects
NCT05966272
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment group A: subjects will receive HRS-7535 tablet orally at dose 1
HRS-7535 tablet
HRS-7535 tablet; low dose
Treatment group B: subjects will receive HRS-7535 tablet orally at dose 2
HRS-7535 tablet
HRS-7535 tablet; middle dose
Treatment group C: subjects will receive HRS-7535 tablet orally at dose 3
HRS-7535 tablet
HRS-7535 tablet; high dose
Treatment group D: subjects will receive HRS-7535 placebo tablet orally.
HRS-7535 placebo tablet
HRS-7535 placebo tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HRS-7535 tablet
HRS-7535 tablet; low dose
HRS-7535 tablet
HRS-7535 tablet; middle dose
HRS-7535 tablet
HRS-7535 tablet; high dose
HRS-7535 placebo tablet
HRS-7535 placebo tablet
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Type 2 diabetes mellitus diagnosed for at least 2 months before the screening visit;
3. HbA1c 7.0-10.0% (both inclusive) at screening;
4. Treated with diet and exercise, and without any antidiabetic drugs at least 8 weeks prior to screening.
Exclusion Criteria
2. Diagnosed or suspected with type 1 diabetes mellitus, special types of diabetes or secondary diabetes.
3. Have a history of acute complications of diabetes (diabetic ketoacidosis, lactic acidosis, hyperglycaemic hyperosmolar state, etc.) within 6 months prior to screening.
4. Proliferative retinopathy, maculopathy, painful diabetic neuropathy, diabetic foot ulcer or intermittent claudication requiring acute treatment;
5. Pregnancy, breast-feeding, intention of becoming pregnant during the trial; or women of childbearing potential (WOCBP) or male subject not using adequate contraceptive measures.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shandong Suncadia Medicine Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HRS-7535-301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.